The state of Kansas currently has 10 active clinical trials seeking participants for Pulmonary Fibrosis research studies. These trials are conducted in various cities, including Wichita, Kansas City, Overland Park and Topeka.
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Recruiting
The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
03/19/2024
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
Recruiting
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
03/15/2024
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
All
Ages:
21 years and above
Trial Updated:
03/13/2024
Locations: University of Kansas Medical Center (KUMC), Kansas City, Kansas
Conditions: Progressive Pulmonary Fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Gender:
All
Ages:
40 years and above
Trial Updated:
03/06/2024
Locations: University of Kansas Medical Center (KUMC), Kansas City, Kansas
Conditions: Idiopathic Pulmonary Fibrosis
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Recruiting
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Gender:
All
Ages:
40 years and above
Trial Updated:
03/01/2024
Locations: The University of Kansas Medical Center, Kansas City, Kansas
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults with Idiopathic Pulmonary Fibrosis.
Gender:
All
Ages:
40 years and above
Trial Updated:
02/29/2024
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Idiopathic Pulmonary Fibrosis
To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF
Recruiting
A participant- and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in participants with idiopathic pulmonary fibrosis
Gender:
All
Ages:
40 years and above
Trial Updated:
02/21/2024
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Idiopathic Pulmonary Fibrosis
Interstitial Lung Disease Research Unit Biobank
Recruiting
Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: The University of Kansas Medical Center, Kansas City, Kansas
Conditions: Interstitial Lung Disease, Sarcoidosis, Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Hypersensitivity Pneumonitis
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Recruiting
This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applied throughout study follow-up, clinical outcome events and patient reported outcome data. Blood samples will be collected periodically throughout the study for use in future research efforts. For participants with non-IPF, chronic fibrosing ILD with progre... Read More
Gender:
All
Ages:
30 years and above
Trial Updated:
11/24/2023
Locations: University of Kansas, Kansas City, Kansas
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
Recruiting
This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.
Gender:
All
Ages:
40 years and above
Trial Updated:
03/06/2023
Locations: University of Kansas Medical Center Research Institute, Inc, Kansas City, Kansas
Conditions: Idiopathic Pulmonary Fibrosis